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Abstract 
Legalization of marijuana use will increase the number of people who will 
become long-term users. A prior medical record review study in Australia, in 
2004, identified 19 chronic marijuana users who entered the emergency 
department with recurrent vomiting associated with abdominal pain. Routine 
treatment of the nausea and vomiting, associated with the chronic marijuana 
abuse, with antiemetics is ineffective in patients with cannabinoid 
hyperemesis syndrome. Narcotics do not relieve the abdominal pain but may 
cause worsening rebound pain. The best treatment of cannabinoid 
hyperemesis syndrome was found to be abstinence from the recreational use 
of marijuana. It is important for advanced practice nurses to place 
cannabinoid hyperemesis syndrome in their differentials of patients 
presenting to the emergency department with recurrent nausea, vomiting, 
and abdominal pain. They need to be knowledgeable about cannabinoid 
hyperemesis syndrome to provide the proper management of care for this 
specific medical condition. 
 
 
Legalization of marijuana use will increase the number of people 
who will become long-term users. A prior medical record review study 
in Australia, in 2004, identified 19 chronic marijuana users who 
entered the emergency department with recurrent vomiting 
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associated with abdominal pain. In the study, long-term users were 
identified as those persons using marijuana on a daily basis or 
monthly. The symptoms improved after taking hot showers or hot 
baths. The hot showers and baths likely worked to correct the 
disequilibrium of the thermoregulatory system of the hypothalamus 
affected by the chronic marijuana use (Allen, DeMoore, Heddle, & 
Twartz, 2004). Usually, the patients did not associate the use of 
marijuana for precipitating the symptoms of nausea, vomiting, and 
abdominal pain (Allen et al., 2004). With more recent research, these 
symptoms of recurrent nausea, vomiting, and abdominal pain have 
been identified as a medical condition named cannabinoid 
hyperemesis syndrome (CHS). The triad of symptoms of CHS is 
identified in recent studies as nausea, vomiting, and abdominal pain, 
relieved by taking hot baths or showers (Simonetto, Oxentenko, 
Herman, & Szostek, 2012; Sontineni, Chaudhary, Sontineni, & 
Lanspa, 2009; Soriano-Co, Batke, & Cappell, 2010; Sun & 
Zimmerman, 2013). These studies supported the findings of Allen et 
al.'s (2004) study. Literature further identifies three phases of cyclic 
vomiting: prodromal, hyperemetic, and the recovery phase (Galli, 
Sawaya, & Friedenberg, 2011). Routine treatment of the nausea and 
vomiting with antiemetics usually is ineffective in patients with CHS. 
Narcotics do not relieve the abdominal pain but may cause worsening 
rebound pain. The best treatment of CHS was found to be abstinence 
from the use of marijuana (Allen et al., 2004; Simonetto et al., 2012; 
Sun & Zimmerman, 2013). 
It is important for advanced practice nurses to be able to 
identify CHS as a potential differential in patients presenting to the 
emergency department with recurrent nausea, vomiting, and 
abdominal pain. They need to be knowledgeable about CHS to provide 
the proper management of care for this specific medical condition. 
 
Case Study 
A 17-year-old adolescent boy entered the emergency 
department with recurrent nausea and vomiting complaining of 
epigastric abdominal pain. As he left triage in a wheelchair, provider 
noticed that he appeared pale, his head was down inside a bucket, he 
was diaphoretic, and he was making loud retching sounds. A nurse 
stated, “This is the second time this week he's been here, he is 
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nothing more than a drug seeker. He has been here two or three 
times every week for the past 3 weeks.” His mother was with him, 
and she appeared concerned and frustrated. She stated, “I want this 
taken care of this time.” A review of his medical records indicated that 
the last time he was seen in the emergency department he was 
admitted as an inpatient with abdominal pain and dehydration. He 
was just discharged the day before yesterday. The diagnosis on the 
discharge summary was cyclic vomiting syndrome. 
While interviewing the patient to obtain a history, he was asked 
about marijuana use. He stated he smoked some yesterday, four to 
five joints. He was discharged from the hospital 48 hr prior with no 
nausea, vomiting, or abdominal pain (he was an inpatient for 48 hr). 
The provider asked his mother whether she was aware that he has 
been smoking marijuana, and she informed me that she was the 
person who purchasing the marijuana (illegally) to help him with his 
nausea and vomiting. 
He was afebrile, tachycardic with a heart rate of 130 beats/min, 
and blood pressure of 110/68 mmHg. Review his physical examination 
and consider how would provider manage his plan of care? 
 
Physical Examination 
 
General 
The patient was pale, diaphoretic, with dry mucous membranes 
and pale skin. 
 
Skin 
Pale and warm to touch; the patient denied itching. 
 
HEENT 
PEERL. No fundoscopic abnormalities. Conjunctivae normal. 
Nose clear without exudates or lesions. Mucous membranes pale and 
dry. Tongue rugged. Slight erythema in posterior pharynx. 
 
Heart 
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No murmurs or rubs. 
 
Lungs 
No crackles or abnormal sounds bilaterally. 
 
Abdomen 
No guarding or rebound; abdomen soft and nondistended, with 
normal bowel sounds. 
 
Genitalia/Rectal 
Stool in the rectum brown, heme negative. 
 
Musculoskeletal/Extremities 
Normal muscle strength in all extremities. Peripheral pulses 2+. 
The patient denied any tenderness. 
 
Neuro 
A and O × 3. No focal weakness. Normal reflexes. Normal 
coordination and gait. 
 
Laboratory Test Results 
The complete blood cell (CBC) count, the chemistry panel, and 
the amylase and lipase were normal. Liver function tests were also 
within normal limits. 
 
Pharmacology Of Cannabis 
The plant genus Cannabis contains 60 cannabinoids unique to 
the plant. Delta-9-tetrahydrocannabinol (THC) is the most potent 
psychoactive agent of the cannabis plant. Other plant cannabinoids 
are cannabinol and cannabidiol. Cannabinoids are found in the stalks, 
leaves, flowers, and seeds of the plant and also within the resin of the 
female plant. Breeding techniques of the cannabis within the past 20 
years has increased the potency of the plant. In 1960, a joint 
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contained about 10 mg of THC, and today a joint contains about 150 
mg of THC (Ashton, 2001). 
When smoking a joint, 50% of the THC is inhaled, absorbed in 
the lungs, and rapidly enters the bloodstream with a peak level 
attained within 2 hr. Cannabis consumed orally reaches blood 
concentrations of 25%–30% of that obtained from smoking. Onset 
effect of the oral consumption is delayed by 0.5–2 hr because of the 
slower absorption from the gut. Absorbed cannabinoids accumulate in 
the fatty tissues of the body, reaching a peak in 4–5 days. Half-life of 
THC is 7 days, and complete clearance takes approximately 30 days 
(Ashton, 2001). 
 
Disease Description and Pathophysiology 
Cannabinoid hyperemesis syndrome is a disease caused by the 
chronic use of cannabis. Consequently, some of the long-term users 
develop recurrent (cyclic) events of nausea associated with violent 
vomiting and colicky, cramping, epigastric, abdominal pain. These 
symptoms may be relieved by taking a hot bath or hot shower; 
however, when the hot bath or shower is completed, the symptoms 
return. Three phases of the disease have been identified as the 
prodromal, hyperemetic, and recovery phases. In the prodromal 
phase, patients may experience some early morning nausea 
associated with the sight or smell of foods; there may be some weight 
loss associated with this phase. There is no compulsive bathing noted 
during this phase. The hyperemesis phase is when the patient starts 
to have profuse vomiting with the colicky, epigastric, abdominal pain. 
It is during this period, the patient learns that the hot baths or 
showers will help with the symptoms. It is also during this phase the 
patients will visit the ED for management of the overwhelming 
vomiting and retching. The recovery phase begins only when cannabis 
use is stopped (Allen et al., 2004; Galli et al., 2011; Price, Fisher, 
Kumar, & Hilgesson, 2011; Soriano-Co et al., 2010; Sun & 
Zimmerman, 2013). 
Tetrahydrocannabinol is the key component in cannabis, and it 
affects the cannabinoid receptor system within the body. The 
cannabinoid receptor system is involved in the physiological processes 
of appetite, pain sensation, mood, and memory. Cannabinoid receptor 
cells identified as cannabinoid receptor 1 (CB1) receptors are located 
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mainly in the brain. CB1 receptors are also located within the 
gastrointestinal system, within the enteric nervous system. The 
effects of THC are mediated mainly by the CB1 receptors. It is the 
CB1 receptors within the gastrointestinal tract that have an effect on 
nausea, vomiting, and gastrointestinal inflammation (Galli et al., 
2011). CB2 receptors are located in the gastrointestinal systems as 
well and only have an immune effect on the body (Galli et al., 2011; 
Pertwee, 2001). Cannabis slows the motility of the gastrointestinal 
tract, helping with nausea and vomiting, and is used medicinally for 
this purpose (Galli et al., 2011). 
Pertwee (2001) documented multiple studies conducted with 
mice, rats, guinea pigs, and humans, showing the effects of THC on 
the gastrointestinal tract. With prescribed doses of THC, an antiemetic 
effect was found. However, pretreatment with a cannabinoid prior to 
the prescribed dose caused a tolerance to the inhibitory effects of the 
cannabinoid, provoking nausea, vomiting, and abdominal pain 
(Pertwee, 2001). This may be the effect seen in the case of a chronic 
marijuana user who exhibits hyperemesis and abdominal pain. 
Another theory is that the toxicity of the CB1 and CB2 cells occurs 
from the chronic use of THC (Simonetto et al., 2012) 
Cannibidiol (CBD) and cannabigerol (CBG), two other 
components of cannabis, appear to regulate the antiemetic properties 
of THC. In animals, it was found that low doses of CBD and CBG had 
an antiemetic effect on the animal; however, high doses of CBD and 
CBG lead to vomiting (Galli et al., 2011). 
 
Differentials for Cyclic Vomiting and Diagnostic 
Criteria 
The differentials for cyclic vomiting would include (but are not 
exclusive to) hyperemesis gravidarum, bulimia, Addison's disease, 
cyclic vomiting, psychogenic vomiting, or pancreatitis. Diagnostic 
tests will help differentiate the diagnosis (see Table 1). Reviewing the 
diagnostic studies of these 116 patients provides guidelines for 
evaluation of the patients with recurrent vomiting. 
 
Diagnostic criteria reviewed in the research conducted by Allen 
et al. (2004), Soriano-Co et al. (2010), and Simonetto et al. (2012) 
are documented in Table 2. The main laboratory tests that were done 
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were CBC count, basic chemistry, amylase, and a urine drug screen. 
Soriano-Co et al. (2010) had eight patients in their study and of 
these only one showed a leukocytosis on the CBC count. Two patients 
had hypokalemia. The amylase level was normal for all eight 
patients. Simonetto et al. (2012) identified 98 patients in their study. 
All of the patients had a normal CBC count, chemistry, and amylase. 
Allen et al. (2004) had 10 patients in their study and results of the 
white blood cell count on the CBC count ranged from 11.5 to 16.9. 
The basic chemistry showed normal potassium and sodium levels. All 
10 patients had negative amylase levels. All 10 patients tested 
positive for cannabis on the urine drug screen. 
Abdominal ultrasonography was done in all of the studies. 
Simonetto et al. (2012) reported that all of the ultrasonograms 
showed normal findings. Allen et al. (2004) reported that nine of the 
10 patients had abdominal ultrasonograms and all nine showed 
normal findings. Soriano-Co et al. (2010) found fatty livers in 12.5% 
of their patients. 
 
Treatment 
There is no documented evidence-based protocol for the 
treatment of CHS. Information in the literature from case studies is 
used as treatment guidelines (Hickey, Witsil, & Mycyk, 2013; Sun & 
Zimmerman, 2013). Guidelines to follow initially when treating CHS 
are to prevent dehydration, correct electrolyte deficiencies, and 
relieve the nausea, vomiting, and abdominal pain. The patient should 
be hydrated with a liter of normal saline. Any antiemetic agent can be 
used for the presenting symptom of nausea and vomiting: 
ondansetron (Zofran), metoclopramide (Reglan), promethazine 
(Phenergan) with diphenhydramine (Benadryl), or prochlorperazine 
(Compazine; Pareek, Fleisher, & Abell, 2007; Wallace, Andrews, 
Garmany, & Jelley, 2011). Abdominal pain initially can be treated with 
morphine or hydromorphone (Dilaudid). When the diagnostic test 
results have returned and ruled out other potential causes of 
recurrent vomiting and abdominal pain, the persistent symptoms 
need to be addressed. In most cases of CHS, the diagnostic test 
results show normal findings (see Table 2). The persistent symptoms 
now need to be addressed. 
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Hickey et al. (2013) identified a patient with CHS in their ED; 
initially, they treated him with a liter of saline, ondansetron (Zofran) 4 
mg intravenously and a single dose of hydromorphone (Dilaudid) for 
his abdominal pain. All of his diagnostic laboratory results showed 
normal findings, and his symptoms persisted. It was decided that the 
patient's symptoms persisted at the same level 1 hr after treatment; 
therefore, a dose of haloperidol (Haldol) 5 mg intravenously was 
tried. After reviewing anesthesia literature related to nausea and 
vomiting postoperatively, it was noted that haloperidol worked; 
therefore, in this case of CHS, Hickey et al. (2013) tried a dose of 
haloperidol (Haldol) 5 mg intravenously. Within 1 hr, all of the 
symptoms subsided and the patient with CHS was discharged home 
with instructions to stop using marijuana. 
Pareek et al. (2007) reviewed literature of case studies related 
to CHS and determined that treatment of CHS should include either 
ondansetron (Zofran) 4 mg intravenously or promethazine 
(Phenergan) 25 mg intravenously with diphenhydramine (Benadryl) 
25–50 mg intravenously. If this treatment of nausea and vomiting 
did not work, it was recommended to use any benzodiazepine to 
promote sleep, which was found to stop the acute episode of 
vomiting. The benzodiazepine they identified in their article was 
lorazepam 1 mg intravenously and it could be repeated every 4 hr as 
needed. A summary of treatment options for the hyperemetic phase 
are given in Table 3. 
 
 
Conclusion 
The patient in our case study did receive Zofran (ondansetron) 
4 mg intravenously for his nausea and Ativan (lorazepam) 1 mg for 
his abdominal pain along with a liter of fluid. When the laboratory 
results were reviewed, the likely cause of symptoms was explained to 
the patient. It was discussed that when he was an inpatient in the 
hospital, he was not using marijuana and his symptoms improved; 
however, when he went home and began smoking marijuana joints, 
all of the symptoms returned with a higher intensity. His mother then 
verbalized her understanding of the situation and wanted to better 
understand why marijuana used for nausea medicinally was not 
working for her son. Educating patients about recreational and over-
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the-counter medication, effects, and side effects is a key component 
of discharge teaching. 
It is important for advanced practice nurses to be able to 
identify CHS in their differentials of patients presenting to the ED with 
recurrent nausea, vomiting, and abdominal pain. They need to be 
knowledgeable about CHS to provide the proper management of care 
for this specific medical condition. 
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Table 2. Literature review: diagnostic results for cannabinoid hyperemesis 
 
Table 3. Treatment options: hyperemetic phase of cannabinoid hyperemesis 
syndrome 
 
 
